Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SCL003
MIFTS: 48

Social Phobia

Categories: Mental diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Social Phobia

About this section

MalaCards integrated aliases for Social Phobia:

Name: Social Phobia 11 14
Phobia, Social 43 71
Phobic Anxiety Disorder 71
Phobia Social 53

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)
ICD10: 31


External Ids:

Disease Ontology 11 DOID:11257
ICD9CM 34 300.23
MeSH 43 D000072861
NCIt 49 C34927
SNOMED-CT 68 192395002
ICD10 31 F40.1
UMLS 71 C0031572 C0349231
Sources

Summaries for Social Phobia

About this section

Disease Ontology: 11 A phobic disorder that involves social anxiety occurring only in specific public or social situations, interactions with others or being evaluated or scrutinized by other people.

MalaCards based summary: Social Phobia, also known as phobia, social, is related to avoidant personality disorder and fragile x syndrome. An important gene associated with Social Phobia is MAOA (Monoamine Oxidase A), and among its related pathways/superpathways are Signal Transduction and GPCR downstream signalling. The drugs Vortioxetine and Norepinephrine have been mentioned in the context of this disorder. Affiliated tissues include prefrontal cortex, brain and cortex, and related phenotypes are Decreased viability and nervous system
Sources

Related Diseases for Social Phobia

About this section

Diseases related to Social Phobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 253)
# Related Disease Score Top Affiliating Genes
1 avoidant personality disorder 31.7 SLC6A4 PIR MAOA
2 fragile x syndrome 31.7 SLC6A4 MAOA FMR1 CRHR1 BDNF
3 stuttering 30.9 HTR3A DRD2 CCK
4 animal phobia 30.6 SLC6A4 OXT
5 body dysmorphic disorder 30.4 SLC6A4 PIR OXT MAOA HTR2A
6 somatization disorder 30.4 SLC6A4 OXT CRH
7 alcohol use disorder 30.3 SLC6A4 SERPINA3 PRODH MAOA DRD2 CRHR1
8 dependent personality disorder 30.3 PIR MAOA
9 panic disorder 30.2 SLC6A4 PRL MAOA HTR3A HTR2A HTR1A
10 delusional disorder 30.2 PRODH HTR2A HTR1A DRD2 COMT
11 premature ejaculation 30.2 SLC6A4 OXT LOC110806262 HTR1A COMT BDNF
12 obsessive-compulsive personality disorder 30.1 SLC6A4 PIR HTR2A COMT
13 speech and communication disorders 30.1 SERPINA3 PRODH OXT COMT BDNF
14 conduct disorder 30.1 SLC6A4 OXTR OXT MAOA DRD2 COMT
15 agoraphobia 30.0 SLC6A4 PRODH PIR MAOA LOC110806262 HTR2A
16 drug dependence 30.0 SLC6A4 MAOA DRD2 CRH COMT BDNF
17 brunner syndrome 29.9 SLC6A4 MAOA HTR3A HTR2A COMT
18 separation anxiety disorder 29.9 SLC6A4 OXTR OXT MAOA HTR1A CTU2
19 personality disorder 29.9 SLC6A4 PRL OXTR MAOA HTR3A HTR2A
20 anxiety 29.8 SLC6A4 PRODH PRL OXTR OXT MAOA
21 cocaine dependence 29.8 SLC6A4 PRL LOC110806262 DRD2 CRH COMT
22 bulimia nervosa 29.7 SLC6A4 OXT MAOA HTR3A HTR2A DRD2
23 schizotypal personality disorder 29.7 PRODH PIR HTR2A DRD2 COMT
24 hypochondriasis 29.7 SLC6A4 PIR OXT MAOA HTR2A HTR1A
25 epilepsy 29.7 PRODH MAOA HTR3A HTR1A CCK BDNF
26 bruxism 29.7 SLC6A4 HTR2A HTR1A DRD2 COMT BDNF
27 schizophreniform disorder 29.6 PRODH PRL HTR2A DRD2 COMT BDNF
28 neurotic disorder 29.6 SLC6A4 OXT MAOA HTR2A HTR1A CRH
29 obsessive-compulsive disorder 29.6 SLC6A4 PRL OXTR OXT MAOA HTR3A
30 withdrawal disorder 29.6 SLC6A4 HTR1A DRD2 CRHR1 CRH BDNF
31 movement disease 29.6 SERPINA3 PRODH HTR2A HTR1A FMR1 DRD2
32 impulse control disorder 29.6 SLC6A4 MAOA HTR2A HTR1A DRD2 COMT
33 oppositional defiant disorder 29.6 SLC6A4 OXTR OXT MAOA HTR2A DRD2
34 gilles de la tourette syndrome 29.5 SLC6A4 MAOA HTR2A HTR1A DRD2 COMT
35 autism spectrum disorder 29.5 SLC6A4 PRODH OXTR OXT MAOA HTR1A
36 atypical depressive disorder 29.5 SLC6A4 SERPINA3 MAOA HTR2A HTR1A CRHR1
37 phobia, specific 29.5 SLC6A4 PRODH PIR OXT MAOA HTR1A
38 dysthymic disorder 29.5 SLC6A4 PRODH PIR OXT MAOA HTR2A
39 major depressive disorder 29.5 SLC6A4 PRL PIR OXT MAOA HTR3A
40 cyclothymic disorder 29.4 SLC6A4 PIR HTR2A HTR1A DRD2 COMT
41 alcohol dependence 29.4 SLC6A4 SERPINA3 MAOA LOC110806262 HTR3A HTR2A
42 autism 29.4 SLC6A4 PRODH OXTR OXT MAOA HTR2A
43 alexithymia 29.4 SLC6A4 PIR OXTR OXT HTR2A DRD2
44 mood disorder 29.4 SLC6A4 SERPINA3 PRODH OXT MAOA HTR3A
45 post-traumatic stress disorder 29.4 SLC6A4 OXTR OXT MAOA HTR2A HTR1A
46 substance abuse 29.3 SLC6A4 SERPINA3 PRODH PRL OXT MAOA
47 generalized anxiety disorder 29.2 SLC6A4 PRODH PIR OXT MAOA LOC110806262
48 acute stress disorder 29.2 SLC6A4 PIR OXT HTR2A CRHR1 CRH
49 schizoaffective disorder 29.2 SLC6A4 SERPINA3 PRODH PRL HTR2A HTR1A
50 eating disorder 29.1 SLC6A4 OXTR OXT LOC110806262 HTR3A HTR2A

Comorbidity relations with Social Phobia via Phenotypic Disease Network (PDN):


Anxiety Dysthymic Disorder

Graphical network of the top 20 diseases related to Social Phobia:



Diseases related to Social Phobia
Sources

Symptoms & Phenotypes for Social Phobia

About this section

GenomeRNAi Phenotypes related to Social Phobia according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00249-S 9.28 SLC6A4
2 Decreased viability GR00381-A-1 9.28 HTR1A HTR3A SLC6A4
3 Decreased viability GR00381-A-3 9.28 HTR1A HTR3A SLC6A4
4 Decreased viability GR00402-S-2 9.28 HTR1A HTR3A

MGI Mouse Phenotypes related to Social Phobia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.2 BDNF CCK COMT CRH CRHR1 DRD2
2 homeostasis/metabolism MP:0005376 10.13 BDNF CCK COMT CRH CRHR1 DRD2
3 endocrine/exocrine gland MP:0005379 9.97 BDNF CCK COMT CRH CRHR1 DRD2
4 no phenotypic analysis MP:0003012 9.91 BDNF CCK CRH CRHR1 DRD2 HTR1A
5 behavior/neurological MP:0005386 9.86 BDNF COMT CRH CRHR1 DRD2 FMR1
6 integument MP:0010771 9.28 BDNF CRH DRD2 HTR3A OXT OXTR
Sources

Drugs & Therapeutics for Social Phobia

About this section

Drugs for Social Phobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
2
Norepinephrine Approved Phase 4 51-41-2 439260
3
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
4
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
5
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
6
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
7
Venlafaxine Approved Phase 4 99300-78-4, 93413-69-5 5656
8
Atomoxetine Approved Phase 4 82248-59-7, 83015-26-3 54841
9
Nefazodone Approved, Withdrawn Phase 4 82752-99-6, 83366-66-9 4449
10
Acamprosate Approved, Investigational Phase 4 77337-73-6, 77337-76-9 71158
11
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
12
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
13
Cariprazine Approved, Investigational Phase 4 839712-12-8 11154555
14
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
15
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
16
Sertraline Approved Phase 4 79617-96-2 68617
17
Topiramate Approved Phase 4 97240-79-4 5284627
18
Dexetimide Withdrawn Phase 4 21888-98-2 30843
19 Serotonin 5-HT3 Receptor Antagonists Phase 4
20
Quetiapine Fumarate Phase 4 111974-72-2
21 Anti-Anxiety Agents Phase 4
22 Serotonin Receptor Agonists Phase 4
23 Serotonin 5-HT1 Receptor Agonists Phase 4
24 Dopamine Agents Phase 4
25 GABA Modulators Phase 4
26 Cytochrome P-450 Enzyme Inhibitors Phase 4
27 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
28 Dopamine Antagonists Phase 4
29 Dopamine agonists Phase 4
30
Desvenlafaxine Succinate Phase 4 386750-22-7
31 Antipsychotic Agents Phase 4
32 Psychotropic Drugs Phase 4
33 Neurotransmitter Agents Phase 4
34
abobotulinumtoxinA Phase 4
35 Botulinum Toxins, Type A Phase 4
36 Botulinum Toxins Phase 4
37 Cholinergic Agents Phase 4
38 Adrenergic beta-Antagonists Phase 4
39 Adrenergic Antagonists Phase 4
40 Adrenergic Agents Phase 4
41 Anti-Arrhythmia Agents Phase 4
42 Antihypertensive Agents Phase 4
43 Vasodilator Agents Phase 4
44 Antidepressive Agents Phase 4
45 Serotonin Uptake Inhibitors Phase 4
46 Anticonvulsants Phase 4
47 Hypoglycemic Agents Phase 4
48
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
49
Memantine Approved, Investigational Phase 3 41100-52-1, 19982-08-2 4054
50
Riluzole Approved, Investigational Phase 2, Phase 3 1744-22-5 5070

Interventional clinical trials:

(show top 50) (show all 269)
# Name Status NCT ID Phase Drugs
1 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
2 A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Unknown status NCT03785223 Phase 4 Methylphenidate Hydrochloride Controlled-Release Capsules;Placebo Capsule
3 D-Cycloserine Enhancement of Exposure in Social Phobia Completed NCT00633984 Phase 4 D-Cycloserine;Placebo
4 The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Effects on Cue Reactivity in Response to Virtual Reality Public Speaking Environment Completed NCT00407199 Phase 4 quetiapine
5 Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Completed NCT00177008 Phase 4 Aripiprazole
6 Phase IV Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder Completed NCT00190879 Phase 4 Atomoxetine hydrochloride;placebo
7 Nefazodone in the Treatment of Social Phobia: Functional Brain Imaging and Neuroendocrine Correlates Completed NCT00231348 Phase 4 Nefazodone
8 Coordinated Anxiety Learning and Management (CALM): Improving Primary Care Anxiety Outcomes Completed NCT00347269 Phase 4 Psychotropic medication optimization
9 The Use of Acamprosate in Individuals With Alcohol Dependence and Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate
10 Improving Outcomes in Pharmacotherapy of Social Phobia Completed NCT00282828 Phase 4 Sertraline;Venlafaxine;Placebo;Clonazepam
11 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
12 A 12-Week Open-Label Study Followed By A 24-Week Double-Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitrilâ„¢ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD) Completed NCT00208741 Phase 4 Gabitril
13 Efficacy and Safety of Escitalopram in Patients With Social Anxiety Disorder; Open-label, One Arm Postmarketing Study in Russia Completed NCT00902226 Phase 4 Escitalopram
14 Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety Completed NCT03522844 Phase 4 Escitalopram
15 A Double-Blind, Placebo-Controlled, Flexible-Dosage Study to Evaluate the Efficacy and Safety of Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Completed NCT01224067 Phase 4 Quetiapine
16 A 12-Week Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Pristiq® (Desvenlafaxine) Extended-Release Tablets in Generalized Social Anxiety Disorder Completed NCT01316302 Phase 4 Pristiq;Placebo
17 A Randomised, Triple Blind, Placebo-controlled Trial Comparing the Effects of Cognitive Therapy, Paroxetine and Both Cognitive Therapy and Paroxetine in the Treatment of Patients With Primary Social Phobia Completed NCT00184106 Phase 4 Seroxat, Cognitive therapy, Seroxat+ cognitive therapy
18 Vraylar® (Cariprazine) in the Treatment of Social Anxiety Disorder: A Double-Blind Study Not yet recruiting NCT05384483 Phase 4 Cariprazine;Placebo
19 A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Social Anxiety Disorder (SAD) Terminated NCT03078270 Phase 4 botulinum toxin A
20 Brief Intervention to Reduce Fear of Public Speaking Terminated NCT02790736 Phase 4 propranolol;Placebo
21 Sertraline in the Treatment of Generalized Social Phobia With Comorbidity Terminated NCT00182533 Phase 4 Sertraline;Placebo
22 Topiramate Augmentation to a Selective Serotonin Re-uptake Inhibitor (SSRI) in Treatment-Resistant Generalized Social Phobia: A Double-Blind Placebo -Controlled Trial. Terminated NCT00182455 Phase 4 Topiramate;Placebo
23 Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice (SophoPrax) Unknown status NCT01388231 Phase 2, Phase 3
24 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder Completed NCT04754802 Phase 3 PH94B Nasal Spray;Placebo Nasal Spray
25 A Feasibility Study for a Phase 3, Randomized, Four-Week, Double-Blind, Placebo-Controlled, Crossover Trial of the Efficacy and Safety of PH94B Nasal Spray in the Acute Treatment of Social Anxiety Disorder (SAD) Completed NCT02622958 Phase 3 PH94B
26 A Single-center, Randomized, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (Oral Extended Release Tablets) to Placebo in Social Phobia Patients and Changes in Their Vasodilatory Response to Methyl-Nicotinate Completed NCT00773162 Phase 3 Seroquel;Sugar Pill
27 D-cycloserine Enhancement of Exposure in Social Phobia Completed NCT00515879 Phase 3 D-cycloserine;Placebo
28 A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder (GAD) or Social Anxiety Disorder (SAD), Who Are Only Partial Responders to Selective Serotonin-Norepinephrine Reuptake Inhibitors (SNRI's) or Selective Serotonin Reuptake Inhibitors (SSRI's). Completed NCT00411398 Phase 3 Namenda/Memantine
29 Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder Completed NCT03017508 Phase 2, Phase 3 BHV-0223;Placebo
30 Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome Completed NCT00114127 Phase 3 Duloxetine;Placebo
31 Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia Completed NCT00958880 Phase 3 Yohimbine Hydrochloride;Sugar Pill
32 Child/Adolescent Anxiety Multimodal Treatment Study Completed NCT00052078 Phase 3 Sertraline (SRT);Placebo
33 Treatment of Childhood Social Phobia Completed NCT00043537 Phase 3 Fluoxetine;Pill Placebo
34 A Systems Level Intervention for Unemployed Persons With Social Anxiety Completed NCT01654510 Phase 2, Phase 3
35 A Comparison Between Internet-based Self-help Therapy and Group Therapy for Social Phobia - A Clinical Equivalence Trial Using Cognitive Behavioural Therapy (CBT) Completed NCT00564967 Phase 3
36 Placebo-Controlled Trial of Hypericum Perforatum in the Treatment of Generalized Social Anxiety Disorder (GSAD) Completed NCT00118833 Phase 2, Phase 3 Hypericum perforatum (St. John's wort)
37 Research Unit on Pediatric Psychopharmacology Anxiety Treatment Study Completed NCT00000389 Phase 3 Fluvoxamine
38 CBT Augmentation of Paroxetine for Social Anxiety Completed NCT00074802 Phase 3 Paroxetine
39 A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Quetiapine in Social Anxiety Disorder Completed NCT00215254 Phase 2, Phase 3 quetiapine
40 Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial Completed NCT00326430 Phase 2, Phase 3
41 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Double-blind, Placebo-controlled Study- <Phase III Study> Completed NCT00318669 Phase 3 Paroxetine hydrochloride hydrate
42 A Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dose Study of Venlafaxine ER In Children and Adolescent Outpatients With Social Anxiety Disorder Completed NCT00238719 Phase 3 Venlafaxine ER
43 Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) -A Open-Label, Uncontrolled, Long-term Study- <Phase III Study> Completed NCT00264654 Phase 3 BRL29060A;paroxetine hydrochloride hydrate
44 Double Blind Placebo Controlled Parallel Group Comparison of Atomoxetine (Strattera) for Generalized Social Anxiety Disorder (GSAD) Completed NCT00260533 Phase 2, Phase 3 atomoxetine;placebo
45 A Randomized, Controlled Study of a Stepped-care Model for the Treatment of Social Phobia and Panic Disorder in Adults Completed NCT00619138 Phase 3
46 Utilizing Health Information Technology to Improve Health Care Quality: Implementation of a Computerized Cognitive Behavioral Therapy Protocol for Childhood Anxiety Completed NCT01416805 Phase 3
47 Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Completed NCT01178385 Phase 2, Phase 3
48 Parent-based Treatment for Youth With Anxiety and Obsessive-compulsive Disorder: Comparison of Therapist-Led and Therapist Assisted Approaches Recruiting NCT04922502 Phase 2, Phase 3
49 A US, Phase 3 Multicenter, Randomized, Double-blind, Placebo Controlled Trial of PH94B Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder (PaliSADe-2) Recruiting NCT05011396 Phase 3 PH94B Nasal Spray;Placebo Nasal Spray
50 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Not yet recruiting NCT03549819 Phase 3 Cannabidiol (CBD) Oil Capsules;Sunflower Lecithin Oil in Capsule

Search NIH Clinical Center for Social Phobia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


gabapentin
gabapentin enacarbil
Paroxetine
Paroxetine Hydrochloride

Cochrane evidence based reviews: phobia, social

Sources

Genetic Tests for Social Phobia

About this section
Sources

Anatomical Context for Social Phobia

About this section

Organs/tissues related to Social Phobia:

MalaCards : Prefrontal Cortex, Brain, Cortex, Amygdala, Cingulate Cortex, Eye, Heart
Sources

Publications for Social Phobia

About this section

Articles related to Social Phobia:

(show top 50) (show all 4016)
# Title Authors PMID Year
1
Association of COMT (Val158Met) and BDNF (Val66Met) gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. 53 62
19582565 2009
2
Impact of prosocial neuropeptides on human brain function. 53 62
18655902 2008
3
Stimuli and consequences of dendritic release of oxytocin within the brain. 53 62
17956324 2007
4
The neuroscience of affiliation: forging links between basic and clinical research on neuropeptides and social behavior. 53 62
16884725 2006
5
Oxytocin modulates neural circuitry for social cognition and fear in humans. 53 62
16339042 2005
6
[Neurobiology and pharmacotherapy of social phobia]. 53 62
15538306 2004
7
Serotonin transporter polymorphism related to amygdala excitability and symptom severity in patients with social phobia. 53 62
15158011 2004
8
Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with 11C McN 5652. 53 62
12457263 2002
9
A preliminary study of dopamine-mediated prolactin inhibition in generalised social phobia. 53 62
12140123 2002
10
Social phobia: diagnosis, severity and implications for treatment. 53 62
10361959 1999
11
Genetic linkage to the serotonin transporter protein and 5HT2A receptor genes excluded in generalized social phobia. 53 62
9925179 1998
12
Placebo-controlled trial of moclobemide in social phobia. 53 62
9534836 1998
13
Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. 53 62
9397424 1997
14
Social phobia: the clinical efficacy and tolerability of the monoamine oxidase -A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. 53 62
8619339 1995
15
[3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers. 53 62
7711158 1995
16
Reversible monoamine oxidase-A inhibitors in social phobia. 53 62
8313403 1993
17
Dataset of physiological, behavioral, and self-report measures from a group decision-making lab study. 62
36426035 2022
18
Problem gambling and anxiety disorders in the general swedish population - a case control study. 62
35380396 2022
19
Experiences of Patients and Therapists Testing a Virtual Reality Exposure App for Symptoms of Claustrophobia: Mixed Methods Study. 62
36469413 2022
20
The longitudinal course of anxiety, depression and apathy through two years after stroke. 62
36063628 2022
21
Brief Cognitive Behavioral Group Therapy and Verbal-Exposure-Augmented Cognitive Behavioral Therapy for Social Anxiety Disorder in University Students: A Randomized Controlled Feasibility Trial. 62
36339696 2022
22
Anxiety disorders, depression and incontinence in preschool children-A population-based study. 62
35979705 2022
23
Prevalence and associated factors of depression, anxiety, and stress among high school students in, Northwest Ethiopia, 2021. 62
36443717 2022
24
Clinical correlates and prognostic impact of binge-eating symptoms in major depressive disorder. 62
35815954 2022
25
Functional connectivity strength and topology differences in social phobia adolescents with and without ADHD comorbidity. 62
36403658 2022
26
Interpretation Biases in Social Scenarios and Social Anxiety: The Role of Safety Behaviors. 62
36268953 2022
27
Evaluation of depression, anxiety and posttraumatic stress response levels of children and adolescents treated with COVID-19. 62
36383286 2022
28
Scary in the eye of the beholder: Attentional bias and attentional retraining for social anxiety. 62
36463629 2022
29
Is helping you helping me? The assessment of helping others using event sampling methodology in a clinical and a non-clinical sample. 62
36329569 2022
30
The effects of anxiety about their parents getting COVID-19 infection on children's mental health. 62
36264340 2022
31
Association between perfectionism and life satisfaction among a sample of the Lebanese population: The indirect role of social phobia and validation of the Arabic version of the Social Phobia Inventory. 62
35383939 2022
32
Development and Effect of Child Obesity Management Program by Applied Nudge. 62
36231990 2022
33
Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes. 62
35656793 2022
34
The development of coronaphobia scale and psychometric effect among UAE people. 62
36210863 2022
35
Drivers and Consequences of Short-Form Video (SFV) Addiction amongst Adolescents in China: Stress-Coping Theory Perspective. 62
36361050 2022
36
The mental health associations of vitiligo: UK population-based cohort study. 62
36268886 2022
37
Religious Involvement and DSM-IV Anxiety Disorders Among African-Americans. 62
35605210 2022
38
Memory bias and personality characteristics in college students with social anxiety disorder. 62
34551240 2022
39
Cognitive-Attentional Syndrome Moderates the Relationship Between Fear of Coronavirus and Symptoms of Coronavirus-Specific Health Anxiety. 62
36313604 2022
40
Psychological Consequences of Fear of COVID-19: Symptom Analysis of Triggered Anxiety and Depression Disorders in Adolescents and Young Adults. 62
36361048 2022
41
German translation and validation of the brief Epilepsy Anxiety Survey Instrument (brEASI). 62
35907288 2022
42
[The application of virtual reality in the treatment of mental disorders]. 62
36053303 2022
43
Autistic spectrum disorder without intellectual impairment in adult mental health services - fostering new perspectives and enhancing existing services. 62
35965060 2022
44
Dual burdens of felt stigma and depressive symptoms in patients with epilepsy: Their association with social anxiety, marriage, and employment. 62
35914436 2022
45
Psychometric properties of Nepalese preschool anxiety scale among preschool children: A cross-sectional study. 62
36090623 2022
46
Internet gaming disorder and its correlates among university students, Saudi Arabia. 62
36389029 2022
47
Assessing the effectiveness of animal-assisted therapy on alleviation of anxiety in pre-school children: A randomized controlled trial. 62
35782634 2022
48
The role of the acceptance and commitment therapy in the treatment of social anxiety: An updated scoping review. 62
35537544 2022
49
Long-term outcome of selective mutism: factors influencing the feeling of being cured. 62
35984502 2022
50
Prevalence of Anxiety Disorder in Adolescents in India: A Systematic Review and Meta-Analysis. 62
36127986 2022
Sources

Variations for Social Phobia

About this section
Sources

Expression for Social Phobia

About this section
Search GEO for disease gene expression data for Social Phobia.
Sources

Pathways for Social Phobia

About this section

Pathways related to Social Phobia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Signal Transduction 66
13.54 OXTR OXT HTR2A HTR1A DRD2 CRHR1
2
GPCR downstream signalling 66
Show member pathways
 13.33 OXTR OXT HTR2A HTR1A DRD2 CRHR1
3
Class A/1 (Rhodopsin-like receptors) 66
Show member pathways
 13.1 OXTR OXT HTR2A HTR1A DRD2 CRHR1
4
Myometrial relaxation and contraction pathways 74
Show member pathways
 12.31 OXTR OXT CRHR1 CRH
5
Sudden infant death syndrome (SIDS) susceptibility pathways 74
11.94 SLC6A4 MAOA HTR3A HTR2A HTR1A BDNF
6
Monoamine GPCRs 74
Show member pathways
 11.75 HTR2A HTR1A DRD2
7
Serotonin and anxiety 74
Show member pathways
 11.02 HTR2A HTR1A FMR1 CRHR1 CRH
8
Neurotransmitter clearance 66
Show member pathways
 10.9 SLC6A4 MAOA COMT
9
Tyrosine metabolism p.1 (dopamine) 22
10.8 MAOA COMT
10
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.8 SLC6A4 MAOA HTR3A HTR2A HTR1A
11
Dopamine metabolism 74
10.62 MAOA COMT
12
Vasopressin-like receptors 66
Show member pathways
 10.54 OXTR OXT
13
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.38 SLC6A4 MAOA HTR1A DRD2 COMT
14
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.28 CRHR1 CRH
15
dopamine degradation 61
10.1 COMT MAOA
Sources

GO Terms for Social Phobia

About this section

Cellular components related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.45 SLC6A4 OXTR HTR3A HTR2A HTR1A DRD2
2 plasma membrane GO:0005887 10.45 SLC6A4 OXTR HTR3A HTR2A HTR1A DRD2
3 dendrite GO:0030425 10.18 HTR2A HTR1A FMR1 DRD2 COMT BDNF
4 synapse GO:0045202 10.15 CRH DRD2 FMR1 HTR1A HTR2A HTR3A
5 axon GO:0030424 10.03 HTR2A FMR1 DRD2 COMT CCK BDNF
6 presynaptic membrane GO:0042734 9.55 SLC6A4 HTR2A FMR1 DRD2
7 obsolete integral component of presynaptic membrane GO:0099056 9.5 SLC6A4 HTR2A DRD2
8 postsynaptic membrane GO:0045211 9.17 SLC6A4 HTR3A HTR2A FMR1 DRD2
9 obsolete integral component of postsynaptic membrane GO:0099055 9.13 SLC6A4 HTR2A DRD2

Biological processes related to Social Phobia according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 PRL OXTR OXT HTR3A HTR2A HTR1A
2 positive regulation of synapse assembly GO:0051965 10.08 OXTR OXT BDNF
3 social behavior GO:0035176 10.03 OXT OXTR SLC6A4
4 response to amphetamine GO:0001975 9.97 OXTR OXT DRD2
5 response to cocaine GO:0042220 9.95 OXTR OXT DRD2
6 eating behavior GO:0042755 9.93 CCK OXT OXTR
7 behavioral response to ethanol GO:0048149 9.9 DRD2 CRHR1
8 drinking behavior GO:0042756 9.89 OXT DRD2
9 dopamine catabolic process GO:0042420 9.88 MAOA COMT
10 positive regulation of uterine smooth muscle contraction GO:0070474 9.88 OXTR OXT
11 negative regulation of voltage-gated calcium channel activity GO:1901386 9.88 FMR1 DRD2 CRHR1
12 neurotransmitter catabolic process GO:0042135 9.87 MAOA COMT
13 negative regulation of gastric acid secretion GO:0060455 9.84 OXTR OXT
14 positive regulation of penile erection GO:0060406 9.83 OXTR OXT
15 positive regulation of norepinephrine secretion GO:0010701 9.81 OXTR OXT
16 sleep GO:0030431 9.8 OXTR OXT HTR2A
17 serotonin receptor signaling pathway GO:0007210 9.73 HTR1A HTR2A HTR3A
18 memory GO:0007613 9.65 SLC6A4 OXTR OXT HTR2A BDNF
19 sperm ejaculation GO:0042713 9.63 SLC6A4 OXTR OXT
20 catecholamine metabolic process GO:0006584 9.61 MAOA COMT
21 behavior GO:0007610 9.55 HTR2A HTR1A
22 regulation of digestive system process GO:0044058 9.37 OXTR OXT
23 female pregnancy GO:0007565 9.32 PRL OXTR OXT CRHR1 CRH

Molecular functions related to Social Phobia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.7 PRL OXT CRH CCK
2 neuropeptide hormone activity GO:0005184 9.43 OXT CRH CCK
3 serotonin binding GO:0051378 9.23 SLC6A4 HTR3A HTR2A HTR1A
Sources

Sources for Social Phobia

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....